β-cyclodextrin complexes of celecoxib: Molecular-modeling, characterization, and dissolution studies

AAPS Journal

Volumn 6, Issue 1, 2004, Pages

  Reddy, M Narender ^a   Rehana, Tasneem ^a   Ramakrishna, S ^a   Chowdary, K P R ^b   Diwan, Prakash V ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b ANDHRA UNIVERSITY   (India)

Author keywords

cyclodextrin; Celecoxib; Complexation; Molecular modeling; Phase solubility

Indexed keywords

BETA CYCLODEXTRIN DERIVATIVE; CELECOXIB; PYRAZOLE DERIVATIVE; BETA CYCLODEXTRIN; CYCLODEXTRIN; NONSTEROID ANTIINFLAMMATORY AGENT; SULFONAMIDE;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; EVAPORATION; FREEZE DRYING; IN VITRO STUDY; MOLECULAR MODEL; SCANNING ELECTRON MICROSCOPY; STOICHIOMETRY; X RAY DIFFRACTION; CHEMICAL STRUCTURE; CHEMISTRY; POWDER; PROTEIN CONFORMATION; SOLUBILITY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; CYCLODEXTRINS; MICROSCOPY, ELECTRON, SCANNING; MODELS, MOLECULAR; POWDERS; PROTEIN CONFORMATION; PYRAZOLES; SOLUBILITY; SULFONAMIDES; X-RAY DIFFRACTION;

EID: 34248661543     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/ps060107     Document Type: Article

References (24)

1. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib. Clin Pharmacokinet. 2000;38:225-242.
2. Simon LS, Lanza FL, Lipsky PE. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor. Arthritis Rheum. 1998;41:1591-1602.
3. Hubbard RC, Koepp RJ, Yu S. SC-58635 (celecoxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pilot study [abstract]. Arthritis Rheum. 1996;39:S226. Abstract 1188.
4. Hubbard RC, Mehlisch DR, Jasper DR. SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post-surgical pain model [Abstract]. J Invest Med. 1996;44: Abstract 293.
5. Paulson SK, Vaughn MB, Jessen SM, et al. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther. 2001;297:638-645.
6. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-442.
7. Szejtli J. Cyclodextrin Technology. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1988:81-83.
8. Loftson T, Brewster ME. Pharmaceutical applications of cyclodextrins.1. Drug solubilization and stabilization. J Pharm Sci. 1996;85:1017-1025.
9. Connors KA. The stability of cyclodextrin complexes in solution. Chem Rev. 1997;97:1325-1357.
10. Uekema K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev. 1998;98:2045-2076.
11. Stella VJ, Rajiwski RA. Cyclodextrins: Their future in drug formulation and delivery. Pharm Res. 1997;14:556-567.
12. Uekama K, Hirayama F. Methods of investigating and preparing inclusion compounds. In: Duchene D, ed. Cyclodextrins and Their Industrial Uses. Paris, France: Editions de Santé; 1987:131-172.
13. Erden N, Celebi N. A study of the inclusion complex of naproxen with β-cyclodextrin. Int J Pharm. 1988;48:83-89.
14. Pop MM, Goubitz K, Borodi G, Bogdan M, De Ridder DJ, Peschar R, Schenk H. Crystal structure of the inclusion complex of beta-cyclodextrin with mefenamic acid from high-resolution synchrotron powder-diffraction data in combination with molecular-mechanics calculations. Acta Crystallogr B. 2002;58:1036-1043.
15. Bonnet P, Jaime C, Morin-Allory L. Alpha-, beta-, and gamma-Cyclodextrin dimers: Molecular modeling studies by molecular mechanics and molecular dynamics simulations. J Org Chem. 2001;66:689-692.
16. Ding HO, Karasawa N, Goddard WA. Atomic level simulations on a million particles: The cell multipole method for Coulomb and London nonbond interactions. J Chem Physiol. 1992; 97 (6):4309-4315.
17. Swope WC, Andersen HC. A computer simulation method for the calculation of equilibrium constants for the formation of physical clusters of molecules: Application to small water clusters. J Chem Physiol. 1982;76(1):637-649.
18. Higuchi T, Connors KA. Phase solubility diagram. Adv Anal Chem Instrum. 1965;4:117-212.
19. Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol. 1975;27:48-49.
20. Furlanetto S, Maestrelli F, Orlandini S, Pinzauti S, Mura P. Optimization of dissolution test precision for a ketoprofen oral extended-release product. J Pharm Biomed Anal. 2003;32:159-165.
21. Marques CH, Hadgraft J, Kellaway I. Studies of cyclodextrin inclusion complexes. I. The salbutamol-cyclodextrin complex as studied by phase solubility and DSC. Int J Pharm. 1990;63:259-266.
22. Uekama K, Hirayama F. Improvement of drug properties by cyclodextrin. In: Wermuth CG, ed. The Practice of Medicinal Chemistry. London, UK: Academic Press; 1996:793-825.
23. Szetli J. Medicinal applications of cyclodextrins. Med Res Rev. 1994;14:353-386.
24. Trapani G, Latrofa A, Franco M, et al. Complexation of Zolpiden with 2-hydroxypropyl-b-, methyl-b-, and 2-hydroxypropyl-g-cyclodextrin: Effect on aqueous solubility, dissolution rate and ataxic activity in rat. J Pharm Sci. 2000;89:1443-1451